ALAoxiang Luo

Aoxiang Luo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aoxiang Luo has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative Trends in the Burden of Depressive Disorders in China and Globally, 1990–2021: Evidence From the Global Burden of Disease 2021

    by Rui Li, Jiawen Huo, Junjiao Ping, Jing Wan, Xuan Ren, Shuyi Zhu, Aoxiang Luo, Tingyun Jiang

    Background:Depressive disorders are among the leading causes of global disability, with steadily increasing incidence and prevalence posing serious challenges to public health systems. As one of the most populous countries worldwide, China’s disease burden trajectory holds significant implications for global mental health trends. However, few studies have systematically compared China’s long-term trends with global patterns. This study aimed to evaluate the disease burden of depressive disorders in China from 1990 to 2021 using Global Burden of Disease Study 2021 (GBD 2021) data and to systematically compare these trends with global trajectories, with additional analysis across age and sex subgroups.Methods:We extracted data on the number of incident cases, prevalent cases, and disability-adjusted life years (DALYs) for depressive disorders, along with their corresponding age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized DALY rate (ASDR) from the GBD 2021 database. Joinpoint regression was used to estimate the estimated annual percentage change (EAPC) and the average annual percentage change (AAPC). The statistical significance of temporal trends was assessed based on 95% confidence intervals and two-sided p values (<0.05), with stratified analyses by age group and sex.Results:From 1990 to 2021, the number of depressive disorder cases in China showed an overall increasing trend, whereas ASIR, ASPR, and ASDR exhibited a gradual overall decline; in contrast, these age-standardized indicators showed a slight overall increase at the global level. Age-stratified analyses showed that ASIR, ASPR, and ASDR increased rapidly among individuals aged 10–24 years in both China and globally. From age 25 onward, the global burden of depressive disorders was mainly concentrated in the 25–49-year age group and declined with increasing age; in China, however, the disease burden remained at relatively high levels among middle-aged and older adults, with ASPR and ASDR peaking in the 40–69-year age group and then declining gradually. Sex-stratified analyses showed that, in both China and globally, females had higher overall disease burden levels than males in terms of incident cases, prevalent cases, DALYs, and corresponding age-standardized indicators.Conclusions:Despite China’s declining standardized burden, depressive disorders remain a major public health concern. The observed differences in age distribution and sex-specific burden, as well as divergent trends between China and global levels, underscore the need for targeted mental health interventions focused on adolescents, older adults, and women. These findings contribute to the evidence base for formulating population-specific mental health policies through a global comparative lens.


  • Open Access

    Apigenin Upregulates Regulatory B Cells, Suppresses Class Switch Recombination, and Restores Immune Homeostasis to Treat Autoimmune Arthritis and Sepsis

    by Hong Chen, Yilian Huang, Yufu He, Menglei Zha, Xin Liu, Tianqiong Lin, Lei Li, Ziyi He, Song Guo Zheng, Yiming Shao, et al.

    Background: Restoring immune homeostasis is crucial for inflammation resolution, in which B cells play dual regulatory roles. A promising therapeutic strategy involves simultaneously suppressing proinflammatory B-cell activity while enhancing regulatory B cells (Bregs). Natural anti-inflammatory compounds, such as the flavonoid apigenin (API), may achieve this dual immunomodulation, yet the precise mechanisms of API on B cells remain incompletely understood. Purpose: This study aimed to elucidate how API modulates B cells to exert immunoregulatory and protective effects in inflammatory conditions. Design: In vitro B-cell functional and molecular assays were integrated with two mechanistically distinct in vivo models—collagen-induced arthritis (CIA) in DBA/1 mice and cecal ligation and puncture (CLP)–induced sepsis in C57BL/6 mice—to evaluate API’s dual immunomodulatory effects and therapeutic potential. Methods: B cells from mouse splenocytes (n=5 per group) or human PBMCs (n=5 healthy donors) were assessed for differentiation, cytokine production, class switch recombination (CSR), and signaling pathways. p38 MAPK involvement was examined using pathway-specific inhibitors. In vivo, disease severity, survival, immune phenotypes, cytokines, and histopathology were evaluated. Results: API increased IL-10⁺ Breg frequency by ~2-fold (P < 0.001) and reduced Aicda expression by ~60% (P < 0.001), while suppressing plasma cell differentiation via Prdm1 downregulation. These effects were p38 MAPK-dependent. In CIA mice, API reduced arthritis scores by ~45% (P < 0.01); in CLP-induced sepsis, 7-day survival improved from 0% to 70% (P < 0.05), with attenuated lung injury and pro-inflammatory cytokine levels. Collectively, API promotes immune homeostasis restoration in both chronic autoimmune and acute inflammatory settings. Conclusion: API restores immune homeostasis in both chronic autoimmune and acute inflammatory settings by coordinating Breg differentiation and suppressing pathogenic B-cell responses, highlighting B-cell-centric immune rebalancing as a promising therapeutic strategy for inflammatory diseases. Plain Language Summary: Excessive inflammation is a defining feature of both chronic autoimmune diseases and acute systemic inflammatory conditions. Restoring immune balance is critical for resolving inflammation—a process in which B cells play dual roles by both promoting and suppressing immune responses. A rational therapeutic strategy, therefore, is to simultaneously curb proinflammatory B cell activity while enhancing the function of immunosuppressive regulatory B cells (Bregs). Natural anti-inflammatory compounds derived from herbal medicine offer a promising source of agents capable of achieving this dual immunomodulation. Apigenin (API), a naturally occurring flavonoid, is known for its broad anti-inflammatory effects. However, whether and how it exerts dual regulatory actions on B cells remains unclear. In this study, we show that API promotes the differentiation of regulatory B cells (Bregs) via activation of the p38 MAPK signaling pathway, suppresses antibody class-switch recombination (a process that generates pathogenic antibodies) through downregulation of the gene Aicda, and inhibits plasma cell differentiation by reducing Prdm1 and IL-6 expression. These coordinated actions underlie its therapeutic efficacy in two distinct models of immune dysregulation. In a mouse model of collagen-induced arthritis—which mimics human rheumatoid arthritis—API alleviated joint inflammation and bone erosion. In a cecal ligation and puncture-induced sepsis model—which replicates severe systemic infection—API improved survival and attenuated acute lung injury. Together, these findings identify B-cell–centered immune rebalancing using natural anti-inflammatory compounds as a promising therapeutic approach for both chronic autoimmune and acute inflammatory conditions. The diagram illustrates the immune status in inflammatory diseases and the therapeutic effects of apigenin (API). On the left, the inflammatory state in diseases like rheumatoid arthritis and sepsis lung injury is depicted, where elevated pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and increased pro-inflammatory cells (macrophages, dendritic cells, T cells) lead to immune imbalance, with reduced regulatory B cells (Breg). On the right, apigenin (API) treatment restores immune balance in these diseases: it activates p38 MAPK signaling to expand Breg cells and increase IL-10 production, while suppressing antibody diversification, plasma cell differentiation, and pro-inflammatory responses. This reduces inflammation and promotes tissue homeostasis, as shown by the normalization of joint and lung conditions. The diagram includes labels for immune cells, antibodies, API, and cytokines, with arrows indicating increases or decreases in activity.Diagram comparing immune imbalance in inflammatory diseases (rheumatoid arthritis, sepsis lung injury) with apigenin (API)-mediated restoration of immune balance and anti-inflammatory effects.

  • Open Access

    Ameliorative Effects of Liquiritin Carbomer Gel on Dinitrofluorobenzene-Induced Atopic Dermatitis in Mice

    by Yun Zhang, Qiqing Tan, Sijia Li, Xiangdi Hu, Aoxiang Luo, Ming Li

    Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by dryness and itching. Steroids are the most common therapeutic agents, may induce skin atrophy, and damage the skin barrier. Therefore, we need to find a safer alternative option. Liquiritin (LQ), a flavonoid compound extracted from licorice rhizomes, possesses anticancer, anti-inflammatory, and antioxidant effects. This study aimed to investigate the therapeutic effects of LQ on AD, focusing on its potential skin barrier-protective and anti-inflammatory mechanisms. In this research, we prepared liquiritin carbomer gel (LQ-CG) and assessed its treatment effects on mice with AD triggered by 2,4-dinitrofluorobenzene (DNFB). It effectively attenuated AD progression by ameliorating skin lesions, decreasing epidermal thickness and mast cell infiltration, downregulating inflammatory cytokine levels, and restoring the expression of claudin-1, loricrin, and occludin. It also inhibited the release of TNF-α, IL-1β, and IL-6 in lipopolysaccharide (LPS)-stimulated RAW264.7 cells, and showed no significant toxicity to major organs in mice. In summary, our findings demonstrate that LQ-CG can effectively alleviate atopic symptoms by repairing the skin barrier and inhibiting inflammatory responses without causing significant changes in organ indices

  • Top Cited Papers
    Open Access

    Interpretable machine learning model for predicting the risk of dysphagia in patients after cardiac surgery

    by Xuan Ren, Junchen Fan, Huajun Wang, Xiangdi Hu, Baizhi Chen, Man Zuo, Yelin Shen, Aoxiang Luo

    Dysphagia is recognized as one of the most common severe complications following cardiac surgery, with the potential to result in adverse clinical outcomes, including aspiration pneumonia, malnutrition, and prolonged hospitalization. Early identification of patients at high risk for postoperative dysphagia is critical for implementing targeted preventive interventions and improving clinical outcomes. However, traditional risk assessment approaches have inherent limitations in accurately predicting this complication. Accordingly, this study was designed to develop and validate a machine learning-based risk prediction model for the accurate identification of patients at high risk for developing dysphagia following cardiac surgery. A prospective observational cohort study design was used to recruit 573 patients undergoing cardiac surgery at Guangdong Provincial People's Hospital between September 2024 and July 2025. Predictor variables included patient demographic characteristics, preoperative risk factors, intraoperative procedural variables, and clinical postoperative indicators. Eight distinct machine learning models were developed for comparison: logistic regression (LR), adaptive boosting (AdaBoost), categorical boosting (CatBoost), extreme gradient boosting (XGBoost), support vector machines (SVM), naive Bayes (NB), k-nearest neighbors (KNN), and gradient boosting machine (GBM). The complete dataset was randomly divided into a 7:3 training-to-test split for model development and validation, respectively. Model performance was evaluated across multiple metrics, including area under the receiver operating characteristic curve (AUC), accuracy, precision, recall, and F1 score. Model calibration performance was assessed using calibration curves, while clinical utility was evaluated through decision curve analysis (DCA). The optimal-performing model was then interpreted and visualized using SHapley Additive exPlanations (SHAP) to enhance model interpretability for clinical implementation. The incidence of postoperative dysphagia among the study cohort was 23.03%. Among all evaluated machine learning models, the GBM demonstrated superior overall performance, achieving a test set AUC of 0.851 (95% CI: 0.781-0.908). This performance was statistically significantly better than that observed with all other models evaluated in the study. The key predictive factors identified by the model included patient age, diabetes, chronic lung disease, chronic kidney disease, atrial fibrillation, tracheal intubation time, gastric intubation time, and sedative drug use duration. Additionally, the GBM model demonstrated excellent calibration performance and high clinical utility, indicating significant potential for integration into routine clinical practice to enable accurate, individualized patient risk assessment. The machine learning model developed in this study demonstrated the ability to accurately identify patients at high risk for postoperative dysphagia, providing a robust foundation for implementing targeted preventive interventions in clinical practice. Integration of this validated machine learning model into standard clinical workflows holds significant promise for reducing the incidence of dysphagia-related complications and improving overall postoperative patient outcomes.


  • Top Cited Papers
    Open Access

    A latent profile analysis of artificial intelligence literacy among undergraduate nursing students: a cross-sectional study

    by Shuyi Zhu, Rui Li, Xuan Ren, Jiawen Huo, Qiqing Tan, Xiangdi Hu, Lin Wang, Lishan Huang, Aoxiang Luo

    To understand the current status of artificial intelligence (AI) literacy among undergraduate nursing students through latent profile analysis, identify po


  • Open Access

    The role of cognitive function in predicting metabolic risk in schizophrenia: a multi-model comparison incorporating clinical features

    by Rui Li, Xuan Ren, Tingyun Jiang, Jiawen Huo, Junjiao Ping, Shuyi Zhu, Aoxiang Luo

    Background: Patients with schizophrenia frequently exhibit metabolic abnormalities that are closely associated with cognitive impairment. However, clinically applicable risk-stratification tools based on concise and generalizable indicators remain limited. This study evaluated the predictive value of cognitive and clinical features for metabolic risk stratification and compared the discriminative performance of traditional statistical and machine-learning models. Methods: In this cross-sectional study, 213 patients with schizophrenia who received treatment at Zhongshan Third People’s Hospital between September 2024 and September 2025 were enrolled according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Based on the diagnostic criteria for metabolic syndrome in the Chinese Guideline for the Prevention and Treatment of Type 2 Diabetes (2017 edition), patients were categorized into three groups: High-risk, Critical, and MS. General clinical data, symptom ratings, and cognitive assessments (Chinese version of the MATRICS Consensus Cognitive Battery, MCCB) were collected. Features were selected using the Boruta algorithm and screened for multicollinearity, followed by the construction of multinomial logistic regression, random forest (RF), extreme gradient boosting (XGBoost), and support vector machine (SVM) models; class imbalance was addressed using SMOTE. Results: Years of education, processing speed, verbal learning, visual learning, and reasoning/problem solving demonstrated stable and independent predictive contributions across models. Age, age at onset, and negative symptoms were also retained during feature selection. The RF model achieved the best overall discriminative performance (macro-average AUC = 0.789; Macro-F1 = 0.603), whereas the SVM model showed superior performance in identifying minority classes (balanced accuracy = 0.725; Macro-F1 = 0.625). These results remained consistent after controlling for clinical symptoms and general demographic variables. Conclusions: Modeling based on concise clinical and cognitive indicators can effectively achieve metabolic risk stratification in patients with schizophrenia. Rather than relying on a single algorithm, combining the complementary strengths of RF and SVM and selecting models according to specific clinical needs and data characteristics may improve the identification of high-risk individuals and support proactive intervention and management.